Last reviewed · How we verify
Autologous Tolerogenic Dendritic cells
Autologous Tolerogenic Dendritic cells is a Dendritic cell therapy Biologic drug developed by Fundacion Clinic per a la Recerca Biomédica. It is currently in Phase 1 development for Autoimmune diseases.
Induction of tolerogenic dendritic cells to suppress immune responses
Induction of tolerogenic dendritic cells to suppress immune responses Used for Autoimmune diseases.
At a glance
| Generic name | Autologous Tolerogenic Dendritic cells |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Dendritic cell therapy |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
Autologous Tolerogenic Dendritic cells work by inducing tolerogenic dendritic cells, which play a crucial role in suppressing immune responses and promoting tolerance to self-antigens.
Approved indications
- Autoimmune diseases
Common side effects
Key clinical trials
- Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis (PHASE2)
- An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes (PHASE1)
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis (PHASE2)
- First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers (PHASE1)
- The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells (PHASE1, PHASE2)
- Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients (PHASE1)
- Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA) (PHASE1)
- Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Tolerogenic Dendritic cells CI brief — competitive landscape report
- Autologous Tolerogenic Dendritic cells updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI
Frequently asked questions about Autologous Tolerogenic Dendritic cells
What is Autologous Tolerogenic Dendritic cells?
How does Autologous Tolerogenic Dendritic cells work?
What is Autologous Tolerogenic Dendritic cells used for?
Who makes Autologous Tolerogenic Dendritic cells?
What drug class is Autologous Tolerogenic Dendritic cells in?
What development phase is Autologous Tolerogenic Dendritic cells in?
Related
- Drug class: All Dendritic cell therapy drugs
- Manufacturer: Fundacion Clinic per a la Recerca Biomédica — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Autoimmune diseases